Effect of aspirin in the adjuvant treatment of gammaglobulin non-reactive Kawasaki disease
Objective:To analyze the effect of aspirin adjuvant therapy on gammaglobulin non-reactive Kawasaki disease(KD).Methods:A total of 77 children with gammaglobulin non-reactive KD treated in our hospital from January 2021 to March 2023 were selected as the study objects.The children were divided into control group(n=38)and observation group(n=39)by random number table method.The control group received routine salvage treatment;Observation group was treated with aspirin on the basis of control group.The duration of clinical symptoms resolution,length of hospital stay,levels of inflammatory factors,adverse reactions and incidence of coronary complications were analyzed and compared between the two groups.Results:After treatment,the remission time of fever,rash,mucosal congestion,neck lymphoid enlargement and hospitalization time in observation group were significantly shorter than those in control group(P<0.05).After treatment,serum C-reactive protein,interleukin-6 and tumor necrosis factor-alpha in both groups were significantly reduced compared with before treatment,and observation group was significantly lower than control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).During 6-month follow-up,the incidence of coronary artery dilation was significantly lower in the observation group than in the control group(P<0.05),but there was no significant difference in the incidence of coronary aneurysm between the two groups(P>0.05).Conclusion:Aspirin adjuvant can shorten the time of symptom resolution,reduce inflammation,and reduce coronary artery dilation in children with gammaglobulin unresponsive KD,with high safety.
Kawasaki diseaseNo response to gamma globulinAspirinAdverse reactionsCoronary artery dilation
NETL
NSTL
万方数据
